GRACE :: Lung Cancer

lorlatinib

Denise Brock

ASCO 2017 – Lung Cancer – Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field – Is there a place for Lorlatinib?

Share

 

H. Jack West, MD 

Medical Director 

Thoracic Oncology Program Swedish Cancer Institute

President & CEO, GRACE 

 

Matthew Gubens, MD

Thoracic Oncologist

Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Cancer Center

Jyoti D. Patel, MD

Director Thoracic Oncology

University of Chicago Medicine


Drs. H. Jack West, Medical Director of the Thoracic Oncology Program at Swedish Cancer Institute in Seattle, Washington and President and CEO of GRACE, Matthew Gubens, Thoracic Oncologist at the Thoracic Surgery and Oncology Clinic of the UCSF Helen Diller Family Comprehensive Center in San Francisco, California, and Jyoti Patel, Director of Thoracic Oncology at University of Chicago Medicine gathered post meeting to discuss new information from ASCO 2017 regarding lung cancer.   In this roundtable video, the doctors discuss  Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field – Is there a place for Lorlatinib? 


 

 


 Please feel free to offer comments and raise questions in our Discussion Forums.


GRACE would like to thank the following sponsors for their support of this program

  
                       

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243